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Abstract: Marine molluscs are rich in biologically active natural products that provide new potential
sources of anti-inflammatory agents. Here we used bioassay guided fractionation of extracts from
the muricid Dicathais orbita to identify brominated indoles with anti-inflammatory activity, based on
the inhibition of nitric oxide (NO) and tumour necrosis factor α (TNFα) in lipopolysaccharide (LPS)
stimulated RAW264.7 macrophages and prostaglandin E2 (PGE2) in calcium ionophore-stimulated
3T3 ccl-92 fibroblasts. Muricid brominated indoles were then compared to a range of synthetic indoles
to determine structure-activity relationships. Both hypobranchial gland and egg extracts inhibited
the production of NO significantly with IC50 of 30.8 and 40 µg/mL, respectively. The hypobranchial
gland extract also inhibited the production of TNFα and PGE2 with IC50 of 43.03 µg/mL and
34.24 µg/mL, respectively. The purified mono-brominated indole and isatin compounds showed
significant inhibitory activity against NO, TNFα, and PGE2, and were more active than dimer indoles
and non-brominated isatin. The position of the bromine atom on the isatin benzene ring significantly
affected the activity, with 5Br > 6Br > 7Br. The mode of action for the active hypobranchial gland
extract, 6-bromoindole, and 6-bromoisatin was further tested by the assessment of the translocation
of nuclear factor kappa B (NFκB) in LPS-stimulated RAW264.7 mouse macrophage. The extract
(40 µg/mL) significantly inhibited the translocation of NFκB in the LPS-stimulated RAW264.7
macrophages by 48.2%, whereas 40 µg/mL of 6-bromoindole and 6-bromoistain caused a 60.7%
and 63.7% reduction in NFκB, respectively. These results identify simple brominated indoles as useful
anti-inflammatory drug leads and support the development of extracts from the Australian muricid
D. orbita, as a new potential natural remedy for the treatment of inflammation.
Keywords: marine natural products; inflammation; NO inhibition; Muricidae; isatin; Tyrian purple
1. Introduction
Inflammation is a complex mechanism involving the activation and deactivation of immune cells
in response to stimuli and tightly regulated signalling pathways. If left unchecked, inflammation will
result in cellular and tissue damage that can lead to chromic disease [1]. Macrophages play a key role
in initiating and maintaining the inflammatory response, and are activated by pathogen associated
molecules and cytokines, which stimulate pro-inflammatory signalling pathways [2]. Nuclear factor
Mar. Drugs 2017, 15, 133; doi:10.3390/md15050133 www.mdpi.com/journal/marinedrugs
Mar. Drugs 2017, 15, 133 2 of 19
kappa B (NFκB) has long been considered a prototypical pro-inflammatory signalling molecule,
activated by pro-inflammatory cytokines such as tumour necrosis factor α (TNFα) in the presence of
viruses, genotoxic agents, or when stimulated by microbial constituents, including lipopolysaccharides
(LPS) from bacterial cell walls [3]. Activation of the inhibitory subunit of NFκB, inhibitor of kappa B
(IκB) kinase, results in the phosphorylation of IκB proteins bound to NFκB. As a consequence, NFκB
translocates to the nucleus, where it regulates the expression of a variety of transcription factors and
co-factors, leading to the expression of pro-inflammatory enzymes like cyclooxygenase 2 (COX-2)
and inducible nitric oxide synthase (iNOS), which are responsible for stimulating the production of
inflammatory signalling molecules [3,4]. TNFα in particular, is considered one of the key inflammatory
mediators in endotoxin-induced tissue injury and high levels of TNFα have been correlated with
the severity of the inflammatory response [5]. Moreover, NO produced by iNOS is a prominent
marker of inflamed tissue and can cause localised toxicity by producing reactive nitrogen oxide species
(RNOS) [6] or by reacting directly with proteins or DNA [7]. Furthermore, prostaglandin E2 (PGE2) is
produced as a result of the combined enzymatic activity of phospholipase A2 (PLA2) and COX-2, which
is also regulated by the activation of NFκB. Therefore, the suppression of excessive production of NO,
TNFα, and/or PGE2 in stimulated cells using in vitro assays provides an effective means to evaluate
the anti-inflammatory activity of natural products and extracts [8] and intracellular translocation of
NFκB can inform the mode of action [3,4].
For many centuries, natural products have provided a significant source of leads for drug
development. Thirty-one marine compounds have now entered the clinical trials pipeline for
drug development, of which seven have been approved by the Food and Drug Administration
(FDA-approved) [9]. In particular, a significant number of anti-cancer drug leads have been isolated
from marine molluscs [10]. However, only a small proportion of natural products isolated from
marine molluscs have been investigated for anti-inflammatory potential [11]. Nevertheless, a lipid
extract from the New Zealand Green lipped mussel Perna canaliculus has been clinically tested for the
treatment of chronic inflammation and is commercially available as a nutraceutical [12]. Preliminary
studies on the crude extracts from whelks in the Muricidae family of predatory gastropods indicate
that these may also yield secondary metabolites with interesting anti-inflammatory properties. The
acetone extracts of Drupella (Drupa) margariticola [13] and chloroform extracts from Purpura persica
significantly reduced carrageenan-induced paw edema in rats, at concentrations well below the toxic
limits [14]. Furthermore, lipid extracts from Rapana venosa were found to reduce inflammation and
improve the healing of skin burns in Wistar rats [15]. These studies support further investigation of the
bioactive compounds in muricid molluscs for potential development as anti-inflammatory treatments
to replace the conventional steroidal and non-steroidal anti-inflammatory drugs, which have numerous
side effects.
The Muricidae are well-known for their production of the dye molecule Tyrian purple
(6,6 dibromoindigo, 1, Table 1) and related biologically active brominated indoles [16]. These
compounds are generated from the precursor indole tyrindoxyl sulfate (2, Table 1), which is stored as a
salt of the choline ester murexine in the hypobranchial glands and egg masses [17]. The intermediate
dye precursors, tyrindoleninone (3, Table 1) and 6-bromoistain (4, Table 1), have specific anticancer
activity, inducing apoptosis in a range of cancer cell lines in vitro [18–22] and DNA damaged cells to
prevent colon cancer in vivo [21,23,24]. These bioactive monobrominated indoles dimerise to form
the green coloured pigment tyriverdin (5, Table 1), the immediate precursor to Tyrian purple, which
has no known anticancer activity but it is a potent bacteriostatic agent [25]. Minor pigments of Tyrian
purple 6,6′-dibromoindirubin and 6-bromoindirubin (6, Table 1) have anti-proliferative properties and
are potent inhibitors of glycogen synthase kinase-3 (GSK-3) [26]. Synthetic bromoindirubin derivatives
with improved solubility and biological selectivity have been developed [27–29], leading to several
patents over the last decade [30–32].
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Table 1. Chemical structure properties and the source of compounds used in the study.
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Depending on the specific mode of action, anti-cancer compounds can often also exhibit
anti-inflammatory activity [3,33,34]. In addition to anti-cancer properties, indirubin (7, Table 1),
a minor pigment in Tyrian purple dye mixtures, prevents the increase of reactive oxygen species (ROS),
causing the attenuation of phagocytosis and induction of cell death in the presence of ATP [21,35].
Indirubin derivatives also inhibit the release of the pro-inflammatory cytokines interleukin (IL)-1β and
IL-6 in mouse macrophage RAW264.7 cells stimulated with LPS [36]. The anti-cancer monobrominated
indoles from Muricidae molluscs are yet to be tested for anti-inflammatory activity. However, the
simple indole derivative isatin (8, Table 1) inhibits iNOS, COX-2, and TNFα, which results in reduced
PGE2 and NO levels in LPS-stimulated mouse macrophages [37]. These isatins, along with some
indole derivatives, have been patented for the treatment of inflammation [38–40]. Consequently,
further investigation of the anti-inflammatory properties of the brominated indoles from Muricidae are
warranted. This study aims to investigate the inhibition of NO, TNFα, PGE2, and NFκB translocation
by extracts and brominated indoles isolated from hypobranchial gland and egg masses of the Muricidae
mollusc Dicathais orbita. In addition, the structure activity relationships of a number of brominated
indoles were examined, using a suite of synthetic indole derivatives to determine if dimerization and
the position of halogenation had any influence on activity.
2. Results
2.1. Chemical Analysis of the Crude Extracts
Liquid chromatography mass spectrometry (LC-MS) separations of the chloroform extracts
confirmed the presence of brominated indoles typically found in D. orbita (Figure 1, Supplementary
Figure S1) [17,22,41]. The fresh hypobranchial gland chloroform extract (Figure 1a) and the egg mass
chloroform extract (Figure 1b) were dominated by 6-bromoistain (pseudomolecular ion [M + H]+
m/z 226, 228; [M + Na]+ m/z 248, 250, UV λmax 212, 256, 308, and 408 nm) and tyrindoleninone
(pseudomolecular ion [M + H]+ m/z 256, 258, UV λmax 236, 248, 274, 352, 402 nm) respectively, and
contained smaller amounts of 6-bromoindole (pseudomolecular ion [M + 2H]+ m/z 198, 200, UV λmax
218, 260, 290 nm) and tyriverdin (pseudomolecular ion [M + Na]+ m/z 535, 537, 539; UV λmax 236,
252, 274, 352, 402, and 596 nm) (Figure S1). Another brominated indole, tentatively identified as
tyrindolinone (C10H10BrNOS2) [17,20], detected in the hydrated form (pseudomolecular ion [M + H]+
306, 308, UV λmax 224, 254, 338 nm), was more abundant in the hypobranchial gland extracts (Figure 1a).
The degraded hypobranchial gland extract did not appear to contain bromoisatin or tyrindoleninone
(Figure 1c), and instead was dominated by unidentified compounds that did not produce paired
isotopic ions indicative of brominated indoles. Due to the lack of anti-inflammatory activity, this
degraded extract was not further characterized. The methanol extract from the hypobranchial gland
(Figure 1d) was dominated by the precursor tyrindoxyl sulfate (pseudomolecular ion detected in
negative ion mode [M]− m/z 336, 338, UV λmax 225 and 300 nm) and contained some murexine ([M]+
m/z 224, UV λmax 266 nm (Figure S1)).
Gas chromatography mass spectrometry (GC-MS) analysis of the hypobranchial gland chloroform
extract further confirmed the dominant volatile compounds in the extract were brominated indoles
(Figure 2, Supplementary Figure S2). Based on comparison to mass spectral databases (≥98% match),
these compounds were identified as methyl 6-bromoisatin, 6-bromo-2,3 dihydro indole-2,3-diol,
6-bromoindoxyl, tyrindoleninone, tyrindoxyl, and 6-bromoisatin (Figure 2a). Tyrindoxyl is a
transient compound that readily oxidizes to tyrindoleninone [42,43]. GC-MS confirmed the purity
of tyrindoleninone in the isolated orange fraction eluted by silica column chromatography with 20%
dichloromethane (DCM) in hexane.




Figure 1. Liquid chromatography mass  spectrometry  (LC‐MS) chromatographs of  several extracts 
from Dicathais orbita showing brominated indoles identified by mass spectrometry (molecular ions for 
Br79, Br81): (a) chloroform extract of the hypobranchial gland; (b) chloroform extract of the egg mass; 
(c)  degraded  chloroform  extract  of  the  hypobranchial  gland;  and  (d)  methanol  extract  of  the 






tyrindoleninone,  with  the  associated  mass  spectral  fragmentation  pattern.  The  brominated 
compounds were  identified based on characteristic mass  isotopic patterns  for brominated  indoles 
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from Dicathais orbita showing brominated indoles identified by mass spectrometry (molecular ions
for Br79, Br81): (a) chloroform extract of the hypobranchial gland; (b) chloroform extract of the egg
mass; (c) degraded chloroform extract of the hypobranchial gland; and (d) methanol extract of the
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2. Gas chromatography mass spectrometry (GC-MS) of the chloroform extracts from
Dicathais orbita showing brominated indoles identified by ass spectrometry (m lecular ions for
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Table 2. Anti-Inflammatory Inhibitory Concentration 50 (IC50) for the brominated indole natural products from Dicathais orbita and synthetic analogues. NA = not
active at maximum test concentration 50 µg/mL; NT = Not tested.
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Tyriverdin is not volatile and is highly insoluble in all solvents. It precipitated out of solution
during LC-MS, hence this semi-purified compound could only be tentatively identified using thin
layer chromatography (TLC; r.f value = 0.32) and the change from a green to purple colour following
exposure to light confirmed that is was mostly likely to be tyriverdin [25].
2.2. Cytotoxicity Assays
There was no cytotoxicity observed for any of the D. orbita extracts used in this study, at
concentrations up to 50 µg/mL, against both RAW264.7 and 3T3 cell lines (Table 2) (cell viability
was 100% in all triplicate wells after 24 h of incubation). Therefore, this concentration was chosen as
the highest concentration for anti-inflammatory testing. However, at 50 µg/mL, 6-bromoindirubin,
tyrindoleninone, 5-bromoisatin, 7-bromoisatin, and 6-bromoindole showed minor toxicity toward
RAW264.7 cells after 24 h of incubation with an average % viability of 56.2%, 84.1%, 55.0%, 81.9%,
and 66.4%, respectively (Table 2). Only 7-bromoisatin showed slight toxicity at 50 µg/mL against
the 3T3 fibroblast cell line after 24 h of incubation, with 80.9% viability when compared to the
DMSO-treated wells.
2.3. NO Inhibition Assay
The chloroform extracts from D. orbita (hypobranchial gland and egg extract) used in this study
showed significant inhibition of NO production by LPS-stimulated RAW264.7 cells at concentrations
down to 10 µg/mL, in comparison to the DMSO control (p < 0.001) (Figure 3A). At the maximum test
concentration of 50 µg/mL, the hypobranchial and the egg extract reduced NO production on average
by 80% and 57% respectively, compared to the well-known anti-inflammatory drug dexamethasone,
which caused 56% inhibition at the working concentration of 2.5 µM (Figure 3A). The methanol
extract and the degraded hypobranchial gland chloroform extract, however, showed no inhibition
of NO production in the LPS-stimulated RAW264.7 mouse macrophages. The methanol extract was
dominated by tyrindoxyl sulfate (Figure 1b), so the lack of NO inhibitory activity in this extracts
indicates that this brominated indoxyl-sufate salt also does not have any associated activity (Table 2).
The purified brominated indoles tyrindoleninone and tyriverdin significantly inhibited the
production of NO, down to 0.08 µg/mL and 10 µg/mL, respectively (p < 0.05, Figure 3B). The IC50 for
tyrindoleninone was 26.4 µg/mL (103 µM), whereas tyriverdin caused less than 50% reduction in NO
at the maximum test concentration (Table 2). The synthetic version of the natural product 6-bromoisatin
significantly inhibited NO production down to 0.4 µg/mL (Figure 3B), with an IC50 of 27.1 µg/mL
(120 µM) (Table 2). The non-brominated compound isatin showed weak NO inhibitory activity causing
on average 34% reduction at 50 µg/mL (Figure 3C), with a predicted IC50 of 63.3 µg/mL (430 µM). The
synthetic 5-bromoisatin had higher activity (Figure 3C) with a predicted IC50 of 34.3 µg/mL (151.6 µM,
Table 1), whilst 7-bromoisatin showed lower activity, with less than 5% inhibition at 50 µg/mL
(Figure 3C). The 6-bromoindole showed similar activity to 5- and 6-bromoisatin (Figure 3C, Table 2).
However, all the synthetic dimers including indirubin, 6,6 dibromoindigo, and 6-bromoindirubin
showed minimal inhibitory activity (Figure 3D).
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Figure 3. NO inhibition in RAW264.7 mouse macrophages stimulated with lipopolysaccharide
(LPS) n treated with extracts from Dicathais orbita, purified brominated indoles, and synth tic
an logues. Data are expressed as % inhibiti n of NO production relative to the negative control
DMSO: (A) extracts from the hypobranchial glands (HBG) and egg capsules; (B) the p ified natural
pro ucts tyrindoleninone an tyriverdin; (C) the monomer synthetic indoles isatin, 5-bromoisatin,
7-br moisatin, and 6-bromoindole; (D) the dimer synthetic indoles indirubin, 6-bromoindirubin, and
6,6 dibromoindigo. Data shown are means ± SEM from thr e separate experiments performed in
triplicate. The symbols above the bars indicate statistically sign ficant differences in the amount of
nitrite in the treatments compared to the DMSO control. * p < 0.05, # p < 0.01, ˆ p < 0. 01, + p < 0. 01
versus untreated, stimulated ce ls (LPS + DMSO).
2.4. TNFα Inhibition
The levels of TNFα in the supernatant were measured in LPS-stimulated RAW264.7 cells
pre-treated for one hour with the chloroform extract from the hypobranchial gland (HBG), isatin,
5-br moisatin, 6-bromoisatin, 6-bromoindole, and tyrindoleninone (Figure 4). The HBG extract showed
significant inhibition of TNFα, down to 0.4 µg/mL (p < 0.01). At 50 µg/mL this extract caused >60%
inhibition of TNFα, which was greater than the positive control dexamethasone (Figure 4A). All the
br minated ind les tested also showed significant inhi ition and for 5-bro oisatin at 50 µg/mL,
inhibition reached 100%, with an IC50 of 38.05 µM (Ta le 2). The IC50 of the non-brominated
indole, isatin, was predicted to be 717.27 µM (above the maximum test concentratio ), and much
less active than the brominated indoles 6-bromoisatin (122.65 µM), 6-bromoindole (150.01 µM), and
tyrindoleninone (157.12 µM) (Table 2).
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2.5. PGE2 Inhibition Assay
The effect of different concentrations of the HBG chloroform extract and the naturally occurring
compounds, 6-bromoisatin and 6-bromoindole, on the generation of PGE2 in 3T3 ccl-92 fibroblast
was examined. The highest inhibition rate was found using the HBG extract, which inhibited the
production of PGE2 by more than 65% at 50 µg/mL (p < 0.0001), which is greater than the inhibition
caused by indomethacin at the 100 µM concentration (Figure 5). In addition, 6-bromoindole caused
a significant dose response for PGE2 inhibition, with significant inhibition compared to the solvent
control even at the lowest concentration (0.08 µg/mL) (p < 0.05) and IC50 of 223.28 µM (Table 2).
Similarly, 6-bromoisatin caused a significant dose response with 40% inhibition at 50 µg/mL and just
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To  investigate  the mode of action of  the active extract and brominated  indoles,  the ability  to 
inhibit  the  translocation  of  the NFκB  in  LPS‐stimulated RAW264.7 was  assessed.  LPS  caused  a 
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Figure 5. PGE2 inhibition in calciu io re sti lated 3T3 ccl-92 fibroblasts after exposure to a
chloroform extract from the hypobranchial glands of icathais orbita and the associated brominated
compounds 6-bromoisatin and 6-bro oindole. Data shown are means ± SEM from three separate
experiments performed in triplicate. Symbols above the bars indicate statistically significant differences
in the amount of PGE2 produced in the samples compared to the DMSO treatment. * p < 0.05, # p < 0.01,
ˆ p < 0.001, + p < 0.0001 versus LPS + DMSO.
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2.6. Assessment of NFκB Translocation
To investigate the mode of action of the active extract and brominated indoles, the ability to
inhibit the translocation of the NFκB in LPS-stimulated RAW264.7 was assessed. LPS caused a marked
increase in the translocation of NFκB into the nucleus, as indicated by significant increases in the red
fluorescence intensity inside the nucleus (Figure 6A,B). The HBG chloroform extract, 6-bromoisatin,
isatin, and 6-bromoindole at 40 µg/mL concentration were all found to cause a noticeable inhibition
of the translocation of NFκB in the LPS-induced RAW264.7 cells, compared to DMSO (Figure 6A).
6-Bromoindole inhibited the translocation of NFκB by 63.2% on average, whereas 6-bromoisatin, HBG







treatment on  the  translocation of  the p65  subunit of  the NFκB  stained with Alexa  fluor  594  (red 
fluorescence)  into  the  nucleus.  The  inhibitor  subunit  was  stained  with  Alexa  fluor  488  (green 




the  synthetic  compounds  6‐bromoisatin,  isatin,  and  6‐bromoindole,  based  on  the  reduction  of 










(chloroform)  extracts  from  the hypobranchial  glands  and  egg masses were  found  to  contain  the 
brominated indole intermediate precursors to Tyrian purple dye [17]. Purification of the chloroform 
extract  led  to  the  isolation  of  tyrindoleninone  and  tyriverdin,  both  of  which  were  found  to 
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Figure 6. The inhibition of nuclear factor kappa B (NFκB) translocation: (A) representative images
of the RAW264.7 cells obtained by an Olympus FV i10 confocal microscope showing the effect of
each treatment on the translocation of the p65 subunit of the NFκB stained with Alexa fluor 594
(red fluorescence) into the nucleus. The inhibitor subunit was stained with Alexa fluor 488 (green
fluorescence) to highlight the inactivated FκB in the cytoplas . 4’,6-Diamidino-2-phenylindole
(DAPI; blue) was used to stain the nucleus. Scale bar set to 10 µm; (B) LPS-induced activation of NFκB
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3. Discussion
The development of new natural products or drugs that prevent the over-production of NO
and pro-inflammatory cytokines, like TNFα and PGE2, has become an important focus of research
for the treatment of chronic inflammatory diseases. In this study, crude organic extracts from the
Australian marine mollusc D. orbita were tested and found to have NO, TNFα, and PGE2 inhibitory
activity, but no cytotoxicity at the active concentrations. Consistent with previous studies, the active
lipophilic (chloroform) extracts from the hypobranchial glands and egg masses were found to contain
the brominated indole intermediate precursors to Tyrian purple dye [17]. Purification of the chloroform
extract led to the isolation of tyrindoleninone and tyriverdin, both of which were found to significantly
inhibit NO production, along with 6-bromoisatin and several other synthetic monobrominated indoles.
By comparison, the synthetic indole dimer pigments and the polar methanol extract containing the
salt precursors, tyrindoxyl sulphate, and murexine, were not found to inhibit the production of NO
in LPS stimulated RAW cells. This indicates that lipophilic extracts from D. orbita containing small
brominated indoles have potential use as anti-inflammatory agents, in addition to their previously
reported anti-cancer properties [21–24].
A range of synthetic brominated indole derivatives were tested to establish the structure-activity
relationships for NO inhibition. Isatin showed mild anti-inflammatory activity, significantly inhibiting
the production of NO with IC50 at ~339.8 µM and TNFα at concentrations down to 0.5 µM (but with
IC50 over the maximum test concentration of 50 µg/mL). This activity is generally consistent with
that reported by Matheus et al. [37], who found that isatin significantly inhibited LPS and interferon-γ
induced NO production in RAW264.7 cells, at even lower concentrations of 10–100 µM, whereas
TNFα was inhibited at 100 µM, although they did not establish the minimum effective dose. These
researchers also tested a range of simple halogenated isatin derivatives and found that whilst most
were active in the test range, the specific activity varied according to the halogen substituent and
position. Likewise, our results indicate that the presence and position of bromine on the aromatic ring
can affect the activity, with 6-bromoisatin > 5-bromoisatin > isatin > 7-bromoisatin for NO inhibition,
whereas for TNFα inhibition, 5-bromoisatin > 6-bromoisatin > isatin. Matheus et al. [37] reported that
4-bromoisatin and 5-iodoisatin did not inhibit NO production or PGE2, whereas three chlorinated
isatin derivatives and 5-flouroisatin inhibited NO and PGE2 at similar concentrations to isatin. In the
TNFα production assay, however, 5-iodoisatin = 6-chloroisatin > isatin > 5-chloroisatin = 7-chloroisatin
> 4-bromoisatin = 4-flouroisatin [37]. These results indicate that the anti-inflammatory activity of
isatins depends on both the position and type of halogen substituent, with different patterns for
TNFα compared to NO and PGE2 inhibition, suggesting that there may be more than one potential
target site or mode of action [37]. Nevertheless, the results from both studies overall suggest that
substitution of bromine into the C5 and C6 position on isatin based compounds effectively increases
the anti-inflammatory activity. Previous studies on the anti-cancer activity of isatin derivatives also
suggest that bromine substitution on C5 or C6 can result in increased biological activity [18,44,45].
In addition to the brominated isatin derivatives, we found similar anti-inflammatory activity with
synthetic 6-bromoindole and naturally derived 6-brominated indole derivatives. This suggests that
the specific functional group in position 2 on the indole ring may not be important for the inhibition
of NO, PGE2, or TNFα. Nevertheless, dimerisation of the indoles was found to substantially reduce
the activity. The lack of inhibitory activity associated with the brominated indirubin and indigo
dimers could be due to their insolubility, as indicated by their calculated log p values of >4 (Table 2).
Kim and Park [36] synthesised a soluble 3 monoxime derivative of indirubin and demonstrated
significant anti-inflammatory activity, including the inhibition of NO and PGE2. However, in our
study, the relatively soluble nonbrominated indirubin was also not active and showed a tendency
towards stimulating the production of NO in LPS stimulated RAW cells. This result was unexpected
given that indirubin is known to inhibit glycogen synthase kinase-3 (GSK3) [45], which promotes
anti-inflammatory responses, including LPS induced NO production [46]. Furthermore, indirubin
has been identified as an active ingredient in the traditional medicinal plants Isatis tinctoria and
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Polyglonum tinctorium used to treat inflammation and has demonstrated in vivo anti-inflammatory
properties [47–49]. Nevertheless, consistent with our results, indigo and alkaloid fractions obtained
from the plant Indigofera suffruticosa have been shown to stimulate NO production [50]. This suggests
indigo and indirubin may have immunomodulatory activity that depends on the specific cell type and
type of stimulation.
Recent studies have showed that many anti-inflammatory drugs, including dexamethasone, can
supress the production of the pro-inflammatory factors by inhibiting the translocation of NFκB [51,52].
Here we provide preliminary evidence that the hypobranchial gland extracts of D. orbita, along
with isatin, 6-bromoisatin, and 6-bromoindole, exerted anti-inflammatory effects by inhibiting the
translocation of NFκB, thus resulting in the inhibition of NO, TNFα, and PGE2 production. Consistent
with this, the indirubin analogue indriubin-3-monoxime was found to downregulate NFκB activation,
correlating with a reduction of inducible NO synthase (iNOS) and cycloxygenase-2 [36]. Inhibiting
the translocation of NFκB prevents the undesirable over production of pro-inflammatory cytokines
and NO from the iNOS pathway. Matheus et al. [37] found that isatin and its halogenated derivatives
significantly inhibit iNOS and COX-2 protein expression, thus resulting in a significant reduction of
NO and PGE2 production. The inhibition of the NFκB translocation signalling pathway is consistent
with the duel anti-inflammatory activities and anti-cancer activities of halogenated indole, isatin, and
indirubin derivatives from Muricidae molluscs [18,20,21,26,53].
In conclusion, this study supports the nutraceutical potential of extracts from the hypobranchial
glands of the Australian muricid D. orbita for anti-inflammatory applications. It also confirms that
simple brominated isatins have anti-inflammatory activity including the inhibition of NO, PGE2, and
TNFα, which are likely to be mediated by the inhibition of NFκB translocation, thus contributing to
their potential application and development as anti-inflammatory and anti-cancer agents.
4. Materials and Methods
4.1. Chemicals and Reagents
Escherichia coli LPS (O128:B12, Sigma), sulfanilic acid, N-(1-Naphthyl) ethylenediamine (NED),
85% orthophosphoric acid sodium nitrite (NaNO2), isatin (8, Table 1), 5-bromoisatin (9, Table 1),
6-bromoisatin (4, Table 1), 7-bromoisatin (10, Table 1), 6-bromoindole (11, Table 1) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Tyrian purple (6,6 dibromoindigo (1, Table 1), indirubin
(7, Table 1), and 6-bromoindirubin (6, Table 1) were obtained from A. L. Skaltsounis (University of
Athens). Penicillin–streptomycin solution, Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine
serum (FBS), sodium pyruvate, and L-glutamine were from Life Technology Australia (Mulgrave, VIC,
Australia). RAW264.7 mouse macrophages and 3T3 Swiss albino (ATCC® CCL92™) cell lines were
obtained from the American Type Culture Collection (ATCC®, Manassas, VA, USA).
4.2. Cell Culture
The Murine RAW264.7 and 3T3 fibroblast cell culture were maintained in 10% FBS supplemented
with DMEM, 100 µg/L streptomycin, and 100 IU/mL penicillin at 37 ◦C and 5% CO2 atmosphere.
Cells were passaged every 48–72 h in a split ratio of 1:10–1:20. Passages used in this study were
between passage 7 and passage 25.
4.3. Mollusc Collection, Dissection, and Extraction
Medium sized Dicathais orbita (40–90 mm shell length) were collected from inter-tidal reefs along
the north coast of NSW, Australia, under the Southern Cross University NSW Fisheries exemption
permit F89/1171-6.0. The collected snails were kept frozen until needed. In addition, the egg capsules
were collected from the same sites during the breeding season in August and stored at −80 ◦C until
needed. The snails were defrosted under running water and the shell was removed by rupturing
it carefully using a bench vice. The hypobranchial glands were excised according to Westley and
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Benkendorff [54] and then weighed on an analytical balance (Mettler-Toledo, Port Melbourne, Australia;
precision 0.0001 g).
The extraction of the secondary metabolites from the collected hypobranchial glands (16.06 g)
or egg capsules (~12 g) was undertaken according to established procedures [20]. Glands or egg
masses were repeatedly soaked for 2 h in solvent (chloroform:methanol, 1:1), and replenished until
a clear extract was obtained. The extract was then filtered through Whatman filter paper 1 (90 mm,
Sigma-Aldrich) to remove the tissue. The filtered solvent was then decanted into a separating funnel,
where the chloroform and the methanol partition were separated with addition of a small amount
of MilliQ water. After the two phases formed, both solvent layers were collected separately then
evaporated to dryness using a rotary evaporator (Buchi, Flawil, Switzerland). The chloroform partition
was kept covered in aluminium foil to protect from photolytic degradation and dried using a vacuum
pressure of 474 mbar at 40 ◦C, then transferred to an amber vial and dried under high purity nitrogen
gas before storage at −80 ◦C. The methanol-water partition was dried using a rotational vacuum
concentrator (Alpha-RVC, Martin Christ, Osterode, Germany) until it was totally dry. In a preliminary
extraction, D. orbita stored for 12 months at −20 ◦C were dissected and the hypobranchical glands,
which had already commenced oxidative and photolytic colour reactions, were used in the extraction.
This extract is referred to as the “degraded HBG extract”. To facilitate dissolving this extract in DMSO
for anti-inflammatory testing, it was sonicated in a water bath for 30 min, then heated at 60 ◦C for
10 min, then further sonicated for 10 min and heated for 10 min two more times. For all other extracts
and compounds examined, the sonication and heating steps were not required to facilitate solubility in
DMSO prior to testing.
4.4. Purification of Brominated Natural Products
The crude chloroform extract from the hypobranchial glands was further fractionated using flash
silica gel column chromatography in order to purify the main indole compounds. The separation of
the compounds based on their colour and polarity by eluting from the silica column with increasingly
polar solvents starting with hexane, then DCM, then increasing concentrations of methanol under
nitrogen pressure, according to Esmaeelian et al. [22]. Six of the fractions were subject to preliminary
bioassay and LC-MS screening and based on these results, further purification focused on the main
brominated indoles tyrindoleninone, tyriverdin, and 6-bromoisatin.
For the separation of tyriverdin from the HBG chloroform extract, the extract was dissolved
in hexane, which results in precipitation out of the solution. The precipitate was then centrifuged
and the solvent was removed, before washing again in hexane, and repeating the procedure until
a clean dried crystaline powder was obtained. To purify tyrindoleninone, the crude hypobranchial
chloroform extract was separated using flash column chromatography pressurised with nitrogen gas.
The stationary phase consisted of a slurry of silica gel 60 (63–200 µm particle size, 70–230 mesh) mixed
with hexane for pouring. Crude extract (426 mg) was loaded onto the column and eluted using a
gradient of solvents. Fraction 1 (~120 mL) was eluted with 100% hexane, fraction 2 (~70 mL) was
eluted with 20% DCM in hexane, fraction 3 (~230 mL) was collected using 25% DCM in hexane, and
fraction 4 with 100% DCM (~250 mL). Fraction 2 containing tyrindoleninone was concentrated in a
rotary evaporator at 40 ◦C and finally dried under N2 gas within amber vials for LC-MS analysis and
activity testing.
4.5. Chemical Analysis of the Extracts and Purified Compounds
Extracts were analysed using an Agilent 1260 Infinity High Performance Liquid Chromatography
(HPLC, Santa Clara, CA, USA) system coupled with a 6120 Quadrupole mass spectrometer (MS)
according the method outlined in Valles-Regino et al. [41]. The HPLC was undertaken on a C18
reversed phase column (100 × 4.6 mm; Phenomenex Luna, Torrance, CA, USA) using a solvent
gradient from 10 to 95% acetonitrile (ACN), both with the addition of 0.005% trifluoroacetic acid (TFA)
over 18 min at a flow rate of 0.75 mL/min. The eluent was also monitored using parallel UV/Vis
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diode-array detection (DAD). The mass spectrometer used electrospray ionisation (ESI) in both positive
and negative ion modes, as well as selected ion monitoring for negatively charged brominated indole
fragment ions at m/z 224, 226. Agilent ChemStation was used to analyse the LC-MS data. Brominated
indoles were identified by comparison of their retention times and characteristic mass spectra (with
major doublet (singly brominated) or triplet (doubly brominated) mass ion clusters separated by
2 mass units for Br78 and Br 81) as reported in previous studies [41,54].
The chloroform extracts and purified tyrindoleninone were also analysed using Gas
chromatography-mass spectrometry (GC-MS) on a Hewlett Packard (HP) 6890 GC coupled to a
HP 5973 mass selective detector (MSD; Palo Alto, CA, USA). The GC utilised a column of HP-5MS
(Crosslinked 5% PH ME Siloxane) with 30 m × 0.25 mm × 0.25 µm film thickness. The column
temperature was controlled by a HP ChemStation programmed from 50 ◦C (5 min hold) to 250 ◦C
(5 min hold) at 10 ◦C/min. The injection volume was 0.2 µL using an Agilent 7683 series injector
with the injection port (split 1:10) at 250 ◦C. Helium was used as the carrier gas with the flow rate of
0.7 mL/min, the MS detector source was set at 250 ◦C and quad at 150 ◦C, with the transfer line at
280 ◦C and ion source voltage of 69.9 eV. Data processing was done using HP ChemStation software
and the identification of the volatile compounds was based on matches to the library mass spectra and
fragmentations patterns (NIST02, WILEY 6, and ESSOILS in house; National Institute of Standards
and Technology, Gaithersberg, MD, USA).
4.6. Preparation of Extracts and Compounds
All extract/compounds were dissolved in DMSO and tested at 5 different concentrations of 50, 10,
2, 0.4, and 0.08 µg/mL for all anti-inflammatory assays unless otherwise noted. The final concentration
of DMSO was 0.35% v/v for extracts and compounds. All samples were tested in triplicate at each
concentration and each assay was independently repeated at least 3 times. The concentrations used for
the cytotoxicity assays were 50, 25, 12.5, 6.25. and 3.125 µg/mL.
4.7. Cytotoxicity Assay
To check for cytotoxicity of the extracts and compounds against RAW264.7 mouse macrophage
and 3T3 ccl-92 mouse fibroblast cell lines, the crystal violet cytotoxicity test was used according to the
published protocol [55]. In brief, RAW264.7 cells were seeded with a density of 2 × 104 cells/well in a
96-well plate and then incubated for 18–24 h. The following day the compounds/extracts were added
and then incubated for 24 h before the media was aspirated and the cells washed twice in a gentle
stream of water. After removing the water, 50 µL of 0.5% crystal violet staining solution were added
and the cells were incubated for 20 min at room temperature. The plate was then washed 4 times
with water and air dried for 2 h. Finally, 200 µL of methanol was added to each well and incubated
for 20 min at room temperature on a rocker. This was followed by measuring the optical density
at 570 nm with a plate reader Anthos Zenyth 200rt (Anthos Labtec Instruments, Heerhugowaard,
The Netherlands). Chlorambucil was used as a positive control.
4.8. NO Inhibition Assay
The NO inhibition assay was conducted according to published procedures [35,56–60]. RAW264.7
macrophages were seeded in a 96 well plate at a concentration of 6 × 105 cells/mL in colour-free 10%
FBS DMEM and incubated at 37 ◦C in 5% CO2 overnight. RAW264.7 macrophages were incubated 1 h
with extracts/compounds prior to the addition of LPS. Dexamethasone at a concentration of 2.5 µM
was used as a positive control and 0.35% DMSO as a negative control. Then, 20 h after the addition
of LPS, the supernatant was collected. The concentration of nitrite in the supernatant was measured
using the Greiss reaction by adding an equal volume of the supernatant and Greiss reagent (0.1%
NED; 1% sulfanilic acid in 5% orthophosphoric acid) in a 96 well plate. The plates were incubated for
15–20 min in the dark, then read at 550 nm wavelength on an Anthos Zenyth 200rt (Anthos Labtec
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Instruments). Sodium nitrite was used to prepare a standard curve to quantify the nitrite from the
absorbance readings in this assay.
4.9. TNF-Alpha Inhibition Assay
The amount of TNFα was quantified in cell culture media using murine TNFα ELISA kits (BD
bioscience). In brief, the RAW264.7 mouse macrophages (6 × 105 cells/mL) were stimulated with
LPS (100 ng/mL) 1 h after treatment with several concentrations of extracts (0.08–50 µg/mL). After
18 h, the supernatant was collected and TNFα production was measured by reading the absorbance
at 450 nm wavelength on an Anthos Zenyth 200rt microplate reader (Anthos Labtech Instruments).
Dexamethasone at a concentration of 2.5 µM was used as a positive control, with a negative control of
0.35% DMSO.
4.10. PGE2 Inhibition Assay
The levels of PGE2 were measured in cell media using a Cayman Prostaglandin E2 Express ELISA
Kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions. In brief,
the 3T3 ccl-92 fibroblasts (1 × 105 cells/mL) were grown overnight in a 96-well plate and then treated
with extracts/compounds 3 h before being stimulated with Calcium ionophore (50 µM). After 20 min,
supernatants were collected and PGE2 production was quantified by measuring the absorbance at
405 nm wavelength with an Anthos Zenyth 200rt (Anthos Labtech Instruments). Indomethacin at a
concentration of 100 µM was used as a positive control and ~0.5% DMSO as a negative control.
4.11. Assessment of NFκB Translocation
This assay was performed according to the published protocol in Olivera et al. [61]. RAW264.7
mouse macrophages were seeded at 400,000 cells/well in 800 µL in 4-well chambered slides and
incubated overnight. The cells were then incubated with the test samples (40 µg/mL HBG extract,
6-bromoisatin, or 6-bromoindole) for 1 h prior to stimulation with LPS (700 ng/mL) for 30 min. After
stimulation, the cells were washed with PBS and fixed with 3.7% paraformaldehyde for 15 min. The
fixed cells were then washed with PBS three times and permeabilised using 0.2% Triton-X 100 for
10 min, followed by a PBS wash and finally blocked using the 0.1% bovine serum albumin (BSA)
for 1 h. The cells were washed with PBS and incubated with rabbit anti-p65 NFκB antibody (1:500)
and goat anti-mouse IκB (1:500) overnight at 4 ◦C. The following day, the cells were washed again
three times with PBS and incubated for 1 h with goat-anti-rabbit IgG conjugated with Alexa Fluor 594
(1:1000) and donkey anti-mouse IgG conjugated with Alexa fluor 488 (1:1000) at room temperature.
Finally, the cells were washed with PBS then mounted with Prolong mounting media containing DAPI
before visualising using the Olympus Flouview FVi10 confocal microscope (Olympus, Tokyo, Japan).
Using ImageJ (v1.50i, National Institutes of Health, Bethesda, MD, USA), an outline was drawn around
each nucleus by adjusting the colour threshold of DAPI. Mean fluorescence inside the nucleus was
measured, along with several adjacent background readings. The total corrected cellular fluorescence
(TCCF) was calculated by applying the equation TCCF = integrated density − (area of selected cell ×
mean fluorescence of background readings) [62]. This TCCF was then used to calculate the %inhibition
of the NFκB translocation against the positive control where the cells were treated with LPS in the
presence of the Vehicle (0.35% DMSO v/v) in Microsoft Office Excel 2013 (Redmond, WA, USA).
4.12. Statistical Analysis
All data were processed in Microsoft Office Excel 2013 (MS) first to obtain descriptive statistics.
One-way Analysis of Variance (ANOVA) followed by Dunnett’s multiple comparisons test was
performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA,
www.graphpad.com), with p < 0.05 considered significant. The inhibitory concentration responsible
for a 50% reduction in cell viability or production of inflammatory markers (IC50) was calculated using
the regression analysis, Probit in SPSS v21.
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